Hospital admissions · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in hospital admission (all cause) compared with tiotropium alone (moderate certainty).
1 finding from 1 review
Hospital admission (exacerbation) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in hospital admission (exacerbation) compared with tiotropium alone (low certainty).
1 finding from 1 review
Mortality (all cause) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in mortality (all cause) compared with tiotropium alone (low certainty).
1 finding from 1 review
Change in baseline trough FEV1 · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
1 finding from 1 review
Mortality (all‐cause) · patients with chronic obstructive pulmonary disease
Tiotropium + LABA/ICS combination showed no clear difference in mortality (all‐cause) compared with tiotropium (moderate certainty).
1 finding from 1 review
Hospital admissions · patients with chronic obstructive pulmonary disease
Tiotropium + LABA/ICS combination showed no clear difference in hospital admission (all causes) compared with tiotropium (low certainty).
1 finding from 1 review
Exacerbations · patients with chronic obstructive pulmonary disease
Tiotropium + LABA/ICS combination showed no clear difference in exacerbation ‐ at 12‐month compared with tiotropium (low certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Tiotropium + LABA/ICS combination showed no clear difference in serious adverse events (non‐fatal) compared with tiotropium (low certainty).
1 finding from 1 review
Quality of life St George's Respiratory Questionnaire (SGRQ) score · patients with chronic obstructive pulmonary disease
1 finding from 1 review
FEV1 · patients with chronic obstructive pulmonary disease
1 finding from 1 review
FEV1 pre‐dose ‐ FEV1 1 year · patients with chronic obstructive pulmonary disease
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Moderate
Hospital admission (exacerbation) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in hospital admission (exacerbation) compared with long‐acting beta2‐agonist alone (low certainty).
1 finding from 1 review
Mortality (all cause) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in mortality (all cause) compared with long‐acting beta2‐agonist alone (low certainty).
1 finding from 1 review
Change in baseline trough FEV1 · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
1 finding from 1 review
Change in quality of life · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life SGRQ responder analysis at 6 months · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium probably leads to higher quality of life SGRQ responder analysis at 6 months compared with long‐acting beta2‐agonist alone (moderate certainty).
1 finding from 1 review
Hospital admissions · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in hospital admission (all cause) compared with long‐acting beta2‐agonist alone (moderate certainty).
1 finding from 1 review
Other measures of lung function: mean change from baseline in FEV1 AUC0-4h (% predicted) after tiotropium 5.0 µg · adults and children with cystic fibrosis
1 finding from 1 review
Change in baseline trough FEV1 · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events after tiotropium 5.0 µg · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found